Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 12/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GIPR | P48546 | 2/20 | 0.38 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | GCG | P01275 | 2/20 | 0.35 |
| ▸ | GLP1R | P43220 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2651260 | 0.89 | GCGR (0.41) | GCGRGIPRSERPINE1CYP2D6DGAT1 | |
| SCHEMBL2651352 | 0.89 | PKM (0.40) | GCGRLMNAGIPRCYP2D6DGAT1 | |
| SCHEMBL2664971 | 0.87 | GCGR (0.47) | GCGRLMNAGIPR | |
| SCHEMBL6751925 | 0.84 | GCGR (0.42) | GCGRGIPRGCGGLP1R | |
| SCHEMBL2650616 | 0.84 | GCGR (0.39) | GCGRGIPRSERPINE1CYP2D6DGAT1 | |
| SCHEMBL6752813 | 0.84 | GCGR (0.50) | GCGRLMNAGIPRGLP1R | |
| SCHEMBL2651309 | 0.83 | DYRK1A (0.39) | GCGRLMNAGIPRCYP2D6DGAT1 | |
| SCHEMBL4096042 | 0.83 | GCGR (0.49) | GCGRGIPRSERPINE1CYP2D6EPHX2 | |
| SCHEMBL2651438 | 0.82 | GCGR (0.58) | GCGRLMNAGIPRGLP1R | |
| SCHEMBL2651825 | 0.82 | GCG (0.43) | GCGRGIPRGCGGLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127560-A1 | Glucagon antagonists/inverse agonists | MADSEN PETER (DK) | 2004-07-01 | — | — | US | claimed |
| US-6706744-B2 | HYPOGLYCEMIC AGENTS; ANTIDIABETIC AGENTS | NOVO NORDISK A/S (DK) | 2004-03-16 | — | — | US | claimed |
| US-20030065031-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2003-04-03 | — | — | US | claimed |
| WO-2002040444-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2002-05-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127560-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | GCGR 3/4885LMNA 3758/4885GIPR 4/4885 |
| US-20030065031-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | GCGR 3/4885LMNA 3758/4885GIPR 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.